Search research articles
Contact Us
Filters
Showing results (81-90 of 88) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 88 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2023
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC
Luckson N Mathieu, Erin Larkins, Arup K Sinha, et al.
Oncogene
|
October 6, 2005
TRF2 inhibition promotes anchorage-independent growth of telomerase-positive human fibroblasts
M Brunori, N Mathieu, M Ricoul, et al.
Revue Medicale De Bruxelles
|
February 15, 2003
[The anesthesiology-recovery department]
M Levarlet, L Barvais, M Baurain, et al.
Journal of Neuroendocrinology
|
December 22, 2015
Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas
N Chauvet, N Romanò, A-C Meunier, et al.
Pathogens and Global Health
|
February 2, 2026
Prevalence of schistosome infection in a region of Madagascar regularly undergoing mass drug administration: a cross-sectional study
Ralf Krumkamp, Aaron Remkes, Jacques Hainasoa, et al.
Journal of Medical Genetics
|
May 24, 2005
A second locus for Aicardi-Goutieres syndrome at chromosome 13q14-21
M Ali, L J Highet, D Lacombe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 88) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 88 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2023
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC
Luckson N Mathieu, Erin Larkins, Arup K Sinha, et al.
Oncogene
|
October 6, 2005
TRF2 inhibition promotes anchorage-independent growth of telomerase-positive human fibroblasts
M Brunori, N Mathieu, M Ricoul, et al.
Revue Medicale De Bruxelles
|
February 15, 2003
[The anesthesiology-recovery department]
M Levarlet, L Barvais, M Baurain, et al.
Journal of Neuroendocrinology
|
December 22, 2015
Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas
N Chauvet, N Romanò, A-C Meunier, et al.
Pathogens and Global Health
|
February 2, 2026
Prevalence of schistosome infection in a region of Madagascar regularly undergoing mass drug administration: a cross-sectional study
Ralf Krumkamp, Aaron Remkes, Jacques Hainasoa, et al.
Journal of Medical Genetics
|
May 24, 2005
A second locus for Aicardi-Goutieres syndrome at chromosome 13q14-21
M Ali, L J Highet, D Lacombe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Page
of 9